NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£111.2m

Last Updated

2021/05/11 18:12 UTC

Data Sources

Company Financials +

Executive Summary

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. More Details


Snowflake Analysis

Exceptional growth potential with excellent balance sheet.

Share Price & News

How has Shield Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: STX is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: STX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

7.2%

STX

-0.9%

GB Pharmaceuticals

-0.5%

GB Market


1 Year Return

-53.4%

STX

-16.7%

GB Pharmaceuticals

24.2%

GB Market

Return vs Industry: STX underperformed the UK Pharmaceuticals industry which returned -12.3% over the past year.

Return vs Market: STX underperformed the UK Market which returned 26.3% over the past year.


Shareholder returns

STXIndustryMarket
7 Day7.2%-0.9%-0.5%
30 Day15.3%3.7%1.5%
90 Day1.0%4.6%6.6%
1 Year-53.4%-53.4%-13.5%-16.7%29.6%24.2%
3 Year92.6%92.6%27.7%14.6%10.6%-2.2%
5 Year-70.7%-70.7%64.7%34.4%47.5%19.5%

Long-Term Price Volatility Vs. Market

How volatile is Shield Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Shield Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: STX (£0.52) is trading below our estimate of fair value (£16.78)

Significantly Below Fair Value: STX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: STX is unprofitable, so we can't compare its PE Ratio to the GB Pharmaceuticals industry average.

PE vs Market: STX is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STX is good value based on its PB Ratio (2x) compared to the GB Pharmaceuticals industry average (4.8x).


Future Growth

How is Shield Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

56.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).

Earnings vs Market: STX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: STX's is expected to become profitable in the next 3 years.

Revenue vs Market: STX's revenue (61.2% per year) is forecast to grow faster than the UK market (5.3% per year).

High Growth Revenue: STX's revenue (61.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: STX's Return on Equity is forecast to be very high in 3 years time (40.2%).


Past Performance

How has Shield Therapeutics performed over the past 5 years?

32.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: STX is currently unprofitable.

Growing Profit Margin: STX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STX is unprofitable, but has reduced losses over the past 5 years at a rate of 32.7% per year.

Accelerating Growth: Unable to compare STX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-11.3%).


Return on Equity

High ROE: STX has a negative Return on Equity (-8.69%), as it is currently unprofitable.


Financial Health

How is Shield Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: STX's short term assets (£5.2M) exceed its short term liabilities (£2.3M).

Long Term Liabilities: STX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: STX is debt free.

Reducing Debt: STX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: STX has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.7% each year.


Dividend

What is Shield Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate STX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Tim Watts (62 yo)

1.08yrs

Tenure

Mr. Timothy William Watts, also known as Tim, serves as Chief Executive Officer and Director at Shield Therapeutics plc since April 21, 2020 and April 24, 2020 respectively. Mr. Watts served as Chief Finan...


Leadership Team

Experienced Management: STX's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: STX's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: STX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 84.2%.


Top Shareholders

Company Information

Shield Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shield Therapeutics plc
  • Ticker: STX
  • Exchange: AIM
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£111.157m
  • Shares outstanding: 215.84m
  • Website: https://www.shieldtherapeutics.com

Number of Employees


Location

  • Shield Therapeutics plc
  • Northern Design Centre
  • Baltic Business Quarter
  • Gateshead
  • Tyne and Wear
  • NE8 3DF
  • United Kingdom

Listings


Biography

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company’s lead product is Ferri...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/11 18:12
End of Day Share Price2021/05/11 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.